|
|
| | basiliximab Basic information |
| Product Name: | basiliximab | | Synonyms: | basiliximab | | CAS: | | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![basiliximab Structure]() |
| | basiliximab Chemical Properties |
| | basiliximab Usage And Synthesis |
| Uses | Immunosuppressant (monoclonal
antibody). | | Brand name | Simulect (Novartis). | | Clinical Use | Basiliximab (Simulect, Chimeric) is an MAb produced by amouse monoclonal cell line that has been engineered to producethe basiliximab IgG1 κ antibody glycoprotein. Theproduct is chimeric (murine/human). Basiliximab is indicatedfor prophylaxis of acute organ rejection in patients receivingrenal transplantation when used as part of a regimenof immunosuppressants and corticosteroids. Basiliximab isalso indicated in pediatric renal transplantation.Basiliximab specifically binds to the IL-2 receptor α-chain(the CD25 antigen, part of the three-component IL-2α receptorsite). These sites are expressed on the surfaces of activatedT lymphocytes. Once bound, it blocks the IL-2α receptor withextremely high affinity. This specific, high-affinity binding toIL-2 competitively inhibits IL-2-mediated activation of lymphocytes,a critical event in the cellular immune response inallograft rejection. | | Drug interactions | Potentially hazardous interactions with other drugs
Ciclosporin: may alter ciclosporin requirements.
Tacrolimus: may alter tacrolimus requirements.
Vaccines: risk of generalised infections with live
vaccines - avoid. | | Metabolism | In vitro studies using human tissues indicate that
basiliximab binds only to activated lymphocytes and
macrophages/monocytes. It is most likely removed by
opsonisation via the reticuloendothelial system when
bound to lymphocytes, or by human antimurine antibody
production. |
| | basiliximab Preparation Products And Raw materials |
|